Loading
AGX-148 is an experimental cell therapy from AgonOx made from the tumour-recognising immune cells in a patient's own tumour. It is in an early trial in solid tumours.
AGX-148 is AgonOx's lead TIL programme. AgonOx sponsors NCT05902520, a phase 1 trial of cancer-specific CD8 tumour-infiltrating lymphocytes in adults with solid tumours, listed on ClinicalTrials.gov as active and not recruiting, and a 2026 National Cancer Institute SBIR award funds its development for breast cancer.
A patient's own CD8 tumour-infiltrating lymphocytes, enriched for the CD39-positive, CD103-positive subset that AgonOx describes as tumour-reactive, expanded and infused back.
1.AGX-148 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AGX-148" OR ABSTRACT:"AGX-148" OR TITLE:"CD39+CD103+ double-positive TIL" OR ABSTRACT:"CD39+CD103+ double-positive TIL") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AGX-148, not a curated reading list.
Shares TIL therapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/